Effectiveness of gentian violet and similar products commonly used to treat pyodermas

Dermatologic Clinics

Volumn 29, Issue 1, 2011, Pages 69-73

  Berrios, Ricardo L ^a   Arbiser, Jack L ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

Gentian violet; Pyoderma; Triphenylmethane; Vascular leak

Indexed keywords

BRILLIANT GREEN; CLINDAMYCIN; COTRIMOXAZOLE; CRYSTAL VIOLET; DOXYCYCLINE; FUCHSINE; LINEZOLID; MALACHITE GREEN; PSEUDOMONIC ACID; TETRACYCLINE;

ALTERNATIVE MEDICINE; ANTIBIOTIC RESISTANCE; BACTERIOSTASIS; BURN; CHEILITIS; CLINICAL TRIAL; CONTACT DERMATITIS; DECUBITUS; DERMATITIS; DERMATOPHYTOSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG USE; ECZEMA; EROSION; HUMAN; IMMUNE RESPONSE; IMPETIGO; INFECTION RISK; INTERTRIGO; LEUKOPENIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MUCOSA INFLAMMATION; NONHUMAN; PARONYCHIA; PRIORITY JOURNAL; PYODERMA; REVIEW; RISK REDUCTION; SEPSIS; SKIN DEFECT; SKIN MANIFESTATION; SKIN NECROSIS; THRUSH; ULCER; VASCULAR DISEASE; WOUND INFECTION;

ANTI-INFECTIVE AGENTS, LOCAL; CAPILLARY PERMEABILITY; GENTIAN VIOLET; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PYODERMA; ROSANILINE DYES; STAPHYLOCOCCAL SKIN INFECTIONS;

EID: 78649338230     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2010.08.009     Document Type: Review

References (25)

1. Graham P.L., Lin S.X., Larson E.L. A U.S. population-based survey of Staphylococcus aureus colonization. Ann Intern Med 2006, 144(5):318-325.
2. Odell C.A. Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) skin infections. Curr Opin Pediatr 2010, 22(3):273-277.
3. Cooke F.J., Brown N.M. Community-associated methicillin-resistant Staphylococcus aureus infections. Br Med Bull 2010, 94:215-227.
4. Sánchez García M., De la Torre M.A., Morales G., et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010, 303(22):2260-2264.
5. Shrand H. Thrush in the newborn. Br Med J 1961, 2:1530-1533.
6. Harvey S.C. Antiseptics and disinfectants; fungicides; ectoparasiticides. The pharmacological basis of therapeutics 1975, 987-1017. Macmillan, New York. L.S. Goodman, A. Gilman (Eds.).
7. Wald E.R., Snyder M.J., Gutberlet R.L. Group B beta-hemolytic streptococcal colonization: acquisition, persistence, and effect of umbilical cord treatment with triple dye. Am J Dis Child 1977, 131:178-180.
8. Bakker P., van Doorne H., Gooskens V., et al. Activity of gentian violet and brilliant green against some microorganisms associated with skin infections. Int J Dermatol 1992, 31:210-213.
9. Churchman J.W. The selective bactericidal action of gentian violet. J Exp Med 1912, 16:221-247.
10. Hinton D. Results of the intravenous use of gentian violet in cases of extreme septicemia. Ann Surg 1925, 81(3):687-692.
11. Saji M. Kansenshogaku Zasshi 1994, 66:914-922. [in Japanese].
12. Saji M., Taguchi S., Uchiyama K., et al. Efficacy of gentian violet in the eradication of methicillin-resistant Staphylococcus aureus from skin lesions. J Hosp Infect 1995, 31:225-228.
13. Okano M., Noguchi S., Tabata K., et al. Topical gentian violet for cutaneous infection and nasal carriage with MRSA. Int J Dermatol 2000, 39(12):942-944.
14. Arbiser J.L., MacKelfresh J., Stoff B. A nonsteroidal alternative to impetiginized eczema in the emergency room. J Amer Acad Dermatol 2010, 63(3):537-539.
15. Brockow K., Grabenhorst P., Abeck D., et al. Effect of gentian violet, corticosteroid and tar preparations in Staphylococcus-aureus-colonized atopic eczema. Dermatology 1999, 199(3):231-236.
16. Docampo R., Moreno S.N.J. The metabolism and mode of action of gentian violet. Drug Metab Rev 1990, 22:161-166.
17. Available at:, Accessed July 23, 2010. http://www.amazon.com/GENTIAN-VIOLET-SOL-2-HUM/dp/B000GCQ05G.
18. Fiedler U., Augustin H.G. Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 2006, 27:552-558.
19. Lowenstein C.J., Morrell C.N., Yamakuchi M. Regulation of Weibel-Palade body exocytosis. Trends Cardiovasc Med 2005, 15:302-308.
20. Davis J.S., Yeo T.W., Piera K.A., et al. Angiopoietin-2 is increased in sepsis and inversely associated with nitric oxide-dependent microvascular reactivity. Crit Care 2010, 14(3):R89.
21. Arbiser JL. High level expression of angiopoietin-2 in human abscesses. J Amer Acad Dermatol, in press.
22. Matsushita K., Morrell C.N., Cambien B., et al. Nitric oxide regulates exocytosis by S-nitrosylation of N-ethylmaleimide-sensitive factor. Cell 2003, 115:139-150.
23. Perry B.N., Govindarajan B., Bhandarkar S.S., et al. Pharmacologic blockade of angiopoietin-2 is efficacious against model hemangiomas in mice. J Invest Dermatol 2006, 126(10):2316-2322.
24. Lapidoth M., Ben-Amitai D., Bhandarkar S., et al. Efficacy of topical application of eosin for ulcerated hemangiomas. J Am Acad Dermatol 2009, 60(2):350-351.
25. Balabanova M., Popova L., Tchipeva R. Dyes in dermatology. Clin Dermatol 2003, 21(1):2-6.